Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…Abstract Number: 1890 • ACR Convergence 2021
Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints and characterized by joint destruction caused by osteoclasts (OC), leading to physical disability. However,…Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…Abstract Number: 0793 • ACR Convergence 2020
Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome
Background/Purpose: Understanding pathogenic processes in the diseased tissue in rheumatoid arthritis (RA) is a critical step to defining disease pathogenesis and identifying novel therapeutic targets.…Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…Abstract Number: 1854 • ACR Convergence 2020
NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…